Skip to main content
main-content

17.09.2016 | Laboratory Investigation | Ausgabe 1/2017

Journal of Neuro-Oncology 1/2017

Jab1 promotes glioma cell proliferation by regulating Siah1/β-catenin pathway

Zeitschrift:
Journal of Neuro-Oncology > Ausgabe 1/2017
Autoren:
Yufu Zhu, Zhichao Qiu, Xiang Zhang, Fengyuan Qian, Bin Wang, Lei Wang, Hengliang Shi, Rutong Yu
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s11060-016-2279-6) contains supplementary material, which is available to authorized users.
Yufu Zhu and Zhichao Qiu have contributed equally to this work.

Abstract

Jab1 (Jun activation domain-binding protein 1), also known as CSN5 (COP9 signalosome subunit 5), is frequently overexpressed in several cancer types. However, the biological functions and the molecular mechanisms of the Jab1 protein in human gliomas have not been investigated. In this study, we found that Jab1 protein was increasingly expressed in human glioma tissues comparing with normal brain tissues (Non-tumor). This suggested that Jab1 might be involved in the development of glioma. Thus, the role of Jab1 in glioma cell proliferation was investigated using Jab1 loss- and gain-of-function. The results showed that downregulation of Jab1 significantly inhibited glioma cell proliferation, while overexpression of Jab1 promoted it. Further investigation on molecular targets revealed that silencing of Jab1 obviously increased the p53 protein level thereby promoting the transcription of ubiquitin ligase Siah1 (Seven in absentia homolog 1), which aggravates the degradation of β-catenin. In contrast, overexpression of Jab1 had the opposite effect. Taken together, these findings suggest that Jab1 promotes glioma cell proliferation and increased expression of Jab1 in glioma patients may amplify β-catenin signaling to contribute to glioma cell proliferation.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der Fachzeitschriften, inklusive eines Print-Abos.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary material 1 Figure 1: (A) Rescue experiment showed the Jab1 shRNA #2 was specific for Jab1. (B and C) EdU assay showed that the shRNA-resistant Jab1 (SR-GFP-Jab1) could abrogate the growth inhibition in the Jab1 shRNA-expressing cells. n.s: no significance, **P < 0.01. (TIF 25502 KB)
11060_2016_2279_MOESM1_ESM.tif
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Journal of Neuro-Oncology 1/2017Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  3. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise